���沙莫瑞林历史与监管定位 — Evidence Review

By Editorial Desk · published 2025-12-25 · last reviewed 2026-01-13 · News

This is a working overview of IGF-1, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-01-13 and is reviewed periodically as new material appears.

特沙莫瑞林历史与监管定位

在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。

特沙莫瑞林是一种合成肽，其序列与人生长激素释放激素的 44 个氨基酸形式相关。它在 N 端带有反式-3-己烯酰基修饰，这一改动可减缓二肽基肽酶 IV 的降解。该化合物属于生长激素释放激素受体激动剂，可刺激垂体释放生长激素。研究文献通常将其归入合成肽类药物，而非小分子化合物。

监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。

Mechanism And Measurement Approaches

Published work tends to frame tesamorelin as a tool for studying the GHRH axis and as a compound with measurable effects on body composition. Reports often describe visceral adipose tissue as an endpoint, assessed by imaging rather than by inference. Analytical sections commonly describe liquid chromatography with tandem mass spectrometry to confirm identity and purity, because immunoassays may cross-react with related fragments. Where results diverge between studies, differences in assay choice, sampling timing, and population are frequent explanations offered. Whether effects persist after treatment stops remains an open question.

Tesamorelin binds the growth hormone–releasing hormone receptor on pituitary somatotroph cells. The receptor signals through the Gs protein, raising intracellular cAMP and activating protein kinase A. That cascade triggers release of stored growth hormone in pulses rather than a steady stream. Because the drug acts at the receptor that normally controls this process, its effect depends on the body's own signaling architecture rather than on a synthetic pathway. The resulting hormone profile reflects the timing of each pulse, not only its size.

Tesamorelin at a glance

Identity and Development Background

Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.

Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.

Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.

Related pages on this site

• Professional digest
• Technical guide
• Portable collection
• Practical update
• Scheduled reference
• Scalable comparison
• Sustainable collection
• Robust toolkit

Storage Handling and Analytical Methods

Storage claims vary across suppliers, and published stability data for specific formulations are limited. Extrapolating from related peptides is common but not a substitute for direct measurement. For research use, documentation such as a certificate of analysis is often requested to confirm identity and purity. What constitutes an acceptable purity threshold depends on the intended application. Open questions remain about how temperature excursions during shipping affect long-term peptide integrity. Independent verification by an end user is not routinely reported.

Lyophilized tesamorelin is generally stored refrigerated at 2 to 8 degrees Celsius, protected from light and moisture. Peptides in this class are often kept frozen at minus 20 degrees Celsius for longer periods. Reconstituted solutions are typically used within a defined window because hydrolysis and oxidation proceed faster in liquid form. Container material and headspace also influence how long a preparation retains its expected profile. Specific stability figures depend on concentration and buffer composition.

Background from the literature

Colum Eastwood, the leader of the Social Democratic and Labour Party, says he "cannot in good conscience" attend this year's St Patrick's Day celebration at White House because of the US response to the Gaza war. Following the first debate of the Safety of Rwanda (Asylum and Immigration) Bill in the House of Lords, Peers vote 206–84 to move the bill on to the next stage of its passage through the House. The Democratic Unionist Party endorses a deal aimed at restoring the Northern Ireland Executive. 30 January – During a visit to the Middle East, Foreign Secretary David Cameron says that the UK is ready to bring forward the moment when it is ready to recognise a Palestinian state. Members of the Senedd vote 39–14 to back the Senedd Reform Bill which expands the legislature to 96 members at the 2026 Senedd election and change the way members are elected. The Media Bill, which proposes changes to radio in the United Kingdom such as reducing regulations for commercial radio and improving access through smart devices, passes its third reading in the House of Commons. 31 January – 2024 Northern Ireland Executive Formation: Details of a deal between the UK government and Democratic Unionist Party aimed at restoring the Northern Ireland Executive are published. It includes reducing checks and paperwork on goods moving between Great Britain and Northern Ireland. Shadow Chancellor Rachel Reeves confirms that Labour would not reintroduce the cap on bankers' bonuses if they form a government after the next general election.

The US Food and Drug Administration (FDA) approves anti-obesity medications as an adjunctive therapy to diet and exercise for people for whom lifestyle changes do not result in sufficient weight loss. In the United States, semaglutide (Wegovy) is approved by the FDA for chronic weight management. The FDA guidelines say that a therapy may be approved if it results in weight loss that is statistically significant greater than placebo and generally at least five percent of body weight over six months that comes predominantly from fat mass. Some other prescription weight loss medications are stimulants, which are recommended only for short-term use, and thus are of limited usefulness for patients who may need to reduce weight over months or years. As of 2022, there is no pathway for approval for drugs that reduce fat mass without 5 percent overall weight loss, even if they significantly improve metabolic health; neither is there one for drugs that help patients maintain weight loss although this can be more challenging than losing weight. As of 2022, no medication has been discovered that would equal the effectiveness of bariatric surgery for long-term weight loss and improved health outcomes.

Because of the activity of manufactured 60Co sources, their radioactivity can present a severe hazard to humans, and can cause death (potentially in less than an hour from acute exposure). After entering a living mammal (such as a human), assuming that the subject does not die shortly after exposure (as may happen in acute exposure incidents), some of the 60Co is excreted in feces. The rest is taken up by tissues, mainly the liver, kidneys, and bones, where the prolonged exposure to gamma radiation can cause cancer. Over time, the absorbed cobalt is eliminated in urine.

Colin Edwards Interviews and Papers about Dylan Thomas, National Library of Wales "Papers of Colin Edwards (d. 1994), a radio journalist of Welsh descent, relating to his incomplete book on Dylan Thomas ('Dylan Remembered')" Dylan Thomas Collection at Harry Ransom Center University of Texas Dylan Thomas Digital Collection at Harry Ransom Center University of Texas & University of Swansea Dylan Thomas Digital Collection from the University at Buffalo Libraries "Archival material relating to Dylan Thomas". UK National Archives. Websites

Holyhead (; Welsh: Caergybi pronounced [kɑːɨrˈɡəbi] , 'Cybi's fort') is a historic port town, and is the largest town and a community in the county of the Isle of Anglesey, Wales. Holyhead is on Holy Island, bounded by the Irish Sea to the north, and is separated from Anglesey island by the narrow Cymyran Strait. It was originally connected to Anglesey via the Four Mile Bridge. In the mid-19th century, Lord Stanley, a local philanthropist, funded the building of a larger causeway, known locally as "the Cobb"; it now carries the A5 and the railway line. The A55 dual carriageway runs parallel to the Cobb on a modern causeway. The town houses the Port of Holyhead, a major Irish Sea port for connections towards Ireland. The population of the town proper as of the 2021 census was 12,084, an increase on the 2011 census.

Sources: en.wikipedia.org

Further detail

Safrole is an organic compound with the formula CH2O2C6H3CH2CH=CH2. It is a colorless oily liquid, although impure samples can appear yellow. A member of the phenylpropanoid family of natural products, it is found in sassafras plants, among others. Small amounts are found in a wide variety of plants, where it functions as a natural antifeedant. Ocotea pretiosa, which grows in Brazil, and Sassafras albidum, which grows in eastern North America, are the main natural sources of safrole. It has a characteristic "sweet-shop" aroma. It is a precursor in the synthesis of the insecticide synergist piperonyl butoxide, the fragrance piperonal via isosafrole, and the empathogenic/entactogenic substance MDMA. In high doses, it is a weak hepatocarcinogen, leading to its ban for human consumption in the United States in the 1960s.

On August 31, 2022, FIFA president Gianni Infantino confirmed that six CONCACAF teams would qualify for the World Cup, with Canada, Mexico, and the United States automatically qualifying as hosts. This was confirmed by the FIFA Council on February 14, 2023. Immediately prior to the 67th FIFA Congress, the FIFA Council approved the slot allocation during a meeting in Manama, Bahrain. This included an inter-confederation playoff tournament involving six teams to decide the last two FIFA World Cup spots. The six teams in the playoffs comprised one team from each confederation excluding UEFA, and one additional team from the confederation of the host countries (CONCACAF). Two of those teams were seeded based on the World Rankings, and they played the winners of two knockout matches between the four unseeded teams for the two FIFA World Cup berths. The four-match tournament was played in Mexico, one of the host countries, and was also used as a test event for the FIFA World Cup. The ratification of slot allocation also gave the OFC a guaranteed berth in the final tournament for the first time: the 2026 FIFA World Cup was the first tournament in which all six confederations had at least one guaranteed berth and also the first time since the 2010 edition in which all confederations had a team qualify for the World Cup finals. Of the 48 qualified teams, 26 also appeared in the 2022 edition. Highlights include:

=== Functional analogues and derivatives === 3,3-Difluoroalanine: Difluorinated alanine with similar residue hydrophobicity to that of isoleucine. 3,3,3-Trifluoroalanine: Trifluorinated alanine that expresses properties of a suicide inhibitor for alanine racemases. 3,3,3-Trifluoroalanine N-carboxyanhydride: A cyclic anhydride of trifluorinated alanine investigated for use as a monomer in homo- and co-polymerisations.

=== Preclinical === 2-Bromo-LSD (bromolysergide; BOL-148; BETR-001, TD-0148A) – non-hallucinogenic serotonin 5-HT2A receptor agonist and other actions ART-2612 (ART2612) – FABP5 inhibitor [25] BMB-202 – serotonin 5-HT2A receptor agonist [26] Cycloserine/lurasidone (NRX-101) – combination of cycloserine (NMDA receptor partial agonist) and lurasidone (atypical antipsychotic or non-selective monoamine receptor modulator) [27] Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (H1 receptor antagonist, muscarinic acetylcholine receptor antagonist, serotonin receptor antagonist, other actions) and prazosin (α1-adrenergic receptor antagonist) [28] GM-3009 (ibogaine analogue(s); GMX-3009) – various actions Leu-enkephalin (leucine enkephalin; Envelta; METDoloron; NES-100; NM-0127; NM-127; PES200) – δ-opioid receptor agonist [29] Metyrapone/oxazepam (EMB-001C; EMB-001) – combination of metyrapone (11β-hydroxylase inhibitor, antiglucocorticoid) and oxazepam (GABAA receptor positive allosteric modulator, benzodiazepine) Midomafetamine microneedle transdermal patch (MDMA; "ecstasy") – serotonin–norepinephrine–dopamine releasing agent, weak serotonin 5-HT2 receptor agonist, and entactogen NB-127 – undefined mechanism of action [30] NNI-351 – DYRK kinase inhibitor, nerve growth factor (NGF) stimulant [31] Prabotulinumtoxin A (ABP-450; DWP-450; Evosyal; Jeuveau; Nabota; Nuceiva) – acetylcholine release inhibitor and neuromuscular blocking agent [32] Research programme: neurotransmitter modulators - Awakn Life Sciences (AWKN-SDN-14) – serotonin–norepinephrine–dopamine reuptake inhibitors [33] TN-001 – non-hallucinogenic serotonin 5-HT2A receptor partial agonist and serotonin 5-HT2B receptor antagonist and neuroplastogen

Sources: en.wikipedia.org

Frequently asked questions